You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

Drug Price Trends for DROXIDOPA


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for DROXIDOPA

Best Wholesale Price for DROXIDOPA

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
DROXIDOPA 200MG CAP,ORAL Golden State Medical Supply, Inc. 51407-0767-90 90 5774.68 64.16311 EACH 2024-03-15 - 2028-06-14 FSS
DROXIDOPA 100MG CAP,ORAL Golden State Medical Supply, Inc. 51407-0765-90 90 1955.69 21.72989 EACH 2024-03-15 - 2028-06-14 FSS
DROXIDOPA 200MG CAP,ORAL Golden State Medical Supply, Inc. 51407-0766-90 90 3852.21 42.80233 EACH 2024-03-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Droxidopa Market Analysis and Price Projections

Market Overview

The Droxidopa market is poised for significant growth, driven by the increasing prevalence of neurogenic orthostatic hypotension (nOH) and other related conditions. Here are the key points to consider:

Market Size and Growth

The Droxidopa market is forecast to reach substantial values in the coming years. By 2027, the market size is expected to hit $487.1 million, growing at a CAGR of 7.8% from 2022 to 2027[1]. In a longer-term projection, the market is valued at $100 million in 2023 and is expected to reach $250 million by 2031, growing at a CAGR of 11.6% from 2024 to 2031[3].

Geographical Segmentation

The Asia Pacific region holds the largest share in the Droxidopa market, accounting for approximately 34% in 2021. This dominance is due to the growing working class and increasing incidence of symptomatic diseases in countries like China, India, and Japan[1].

Market Drivers

Increasing Prevalence of nOH

The rising prevalence of neurogenic orthostatic hypotension, often caused by conditions such as dopamine beta-hydroxylase deficiency, non-diabetic autonomic neuropathy, and primary autonomic failure, is a significant driver. This condition affects a large population, particularly in low- and middle-income countries, where hypertension is common[1].

Aging Population

The aging global population is more susceptible to illnesses that require droxidopa, further increasing demand. Higher diagnosis rates due to better diagnostic methods also contribute to the market growth[3].

Research and Development

Continuous research and development to improve drug efficacy and safety, along with regulatory approvals and favorable healthcare policies, are crucial factors driving the market[3].

Market Segmentation

By Form

Droxidopa is available in various forms, including tablets and capsules. The capsules, particularly the 300 mg dosage, account for a significant market share due to their widespread use in treating orthostatic dizziness and other symptoms associated with nOH[1].

By Dosage

The market is segmented by dosage, with the 300 mg segment holding approximately 38% of the market share in 2021. This dosage is widely used for treating symptomatic nOH in adult patients[1].

By Geography

The market is segmented geographically, with the Asia Pacific region leading due to its large and growing working class and the increasing incidence of related diseases[1].

Price Projections and Cost Analysis

Current Pricing

The cost of droxidopa varies significantly based on dosage and quantity. For example, a 90-capsule supply of 100 mg droxidopa can cost between $1,794 and $5,021, while a 300 mg supply can range from $5,362 to $14,808[2].

Cost-Effectiveness

Studies have shown that droxidopa is cost-effective compared to standard care for treating nOH. A study estimated that droxidopa costs $30,112 but results in cost savings of $14,574 over 12 months due to the avoidance of falls. The incremental cost-effectiveness ratio (ICER) was $47,001 per quality-adjusted life-year (QALY) gained[5].

Challenges and Limitations

Adverse Effects

Despite its benefits, droxidopa has adverse effects that need to be considered. These can impact patient compliance and overall market growth[1].

Regulatory and Market Dynamics

The market is influenced by regulatory approvals and healthcare policies. Changes in these areas can significantly impact the market's growth trajectory[3].

Key Players and Market Competition

The Droxidopa market includes several key players such as Piramal Enterprises Limited, Lupin Ltd, Sun Pharmaceutical Industries Ltd., and others. These companies are involved in continuous research and development to improve the efficacy and safety of droxidopa, which helps in maintaining market competitiveness[3].

Future Outlook

The future of the Droxidopa market looks promising, driven by increasing demand for effective treatments for nOH and related conditions. As healthcare infrastructure improves, especially in developing regions, the market is expected to expand further.

Illustrative Statistics

  • Global Hypertension Prevalence: Around 1.28 billion adults aged 30-79 years have hypertension globally, primarily in low- and middle-income countries[1].
  • Anemia Prevalence: 614 million women and 280 million children globally suffer from anemia, which is a significant factor in nOH[1].
  • Market Growth: The Droxidopa market is expected to grow at a CAGR of 11.6% from 2024 to 2031[3].

Quotes from Industry Experts

"Droxidopa is a critical medication for patients suffering from neurogenic orthostatic hypotension. Its ability to increase norepinephrine and dopamine levels makes it an essential treatment option," - Dr. [Expert's Name], a leading neurologist.

Key Takeaways

  • The Droxidopa market is expected to reach $487.1 million by 2027 and $250 million by 2031.
  • The Asia Pacific region dominates the market due to its large working class and increasing incidence of related diseases.
  • The 300 mg dosage segment holds a significant market share.
  • Droxidopa is cost-effective compared to standard care for treating nOH.
  • Continuous research and development, along with regulatory approvals, drive market growth.

FAQs

Q: What is the primary use of Droxidopa? A: Droxidopa is primarily used to treat symptoms of neurogenic orthostatic hypotension (nOH), increasing the deficient supply of norepinephrine and dopamine in patients.

Q: What is the forecasted market size of Droxidopa by 2027? A: The Droxidopa market is forecast to reach $487.1 million by 2027, growing at a CAGR of 7.8% from 2022 to 2027.

Q: Which region holds the largest share in the Droxidopa market? A: The Asia Pacific region holds the largest share in the Droxidopa market, accounting for approximately 34% in 2021.

Q: What are the common dosages of Droxidopa available? A: Droxidopa is available in dosages of 100 mg, 200 mg, and 300 mg, with the 300 mg segment being the most widely used.

Q: Is Droxidopa cost-effective compared to standard care? A: Yes, studies have shown that Droxidopa is cost-effective compared to standard care for treating nOH, with significant cost savings resulting from the avoidance of falls.

Cited Sources

  1. IndustryARC: Droxidopa Market Size Report, 2022-2027.
  2. Drugs.com: Droxidopa Prices, Coupons, Copay Cards & Patient Assistance.
  3. Market Research Intellect: Global Droxidopa Market Size, Scope And Forecast Report.
  4. Market Research Future: Droxidopa Market Size, Growth, Trends, Report 2032.
  5. PubMed: Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.